Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDX submitted a Form 144 reporting an intended transfer related to 7,771 shares of Common Stock tied to the vesting of restricted stock units on 05/19/2026 for services rendered. The filing also lists recent dispositions by John E. Bishop on 02/20/2026 totaling 3,179 shares (2,792; 386; 1) with aggregate proceeds shown.
An insider transaction related to restricted stock units for the issuer was disclosed on 05/19/2026. The filing shows 24,041 shares tied to vesting of restricted stock units and lists prior open-market sales by Laura A. Williams on 02/20/2026 of 7,192 shares and 984 shares for proceeds of $42,181.08 and $5,622.38, respectively. The form reports Common Stock transactions for the account held with Morgan Stanley Smith Barney LLC.
ARDELYX, INC. President & CEO Michael Raab reported an open-market sale and an option exercise involving the company’s common stock. He sold 41,666 shares on May 15, 2026 at a weighted average price of $6.2788 per share under a pre-arranged Rule 10b5-1 trading plan.
On the same date he exercised 20,833 stock options at a strike price of $0.99 per share, receiving the underlying common shares. After these transactions he held 1,814,447 shares of common stock directly and 332,501 stock options, plus indirect holdings of 1,000 and 24,364 shares through family trusts.
Janus Henderson Group plc reports beneficial ownership of 8,371,234 shares of Ardelyx common stock as of 03/31/2026. The filing states this equals 3.4% of the class and that the Asset Managers exercise shared voting and shared dispositive power over those shares. The filing describes the positions as held through multiple Janus Henderson asset‑management entities and includes a statement disclaiming rights to receive dividends or sale proceeds on behalf of those Asset Managers; the filing also notes the Managed Portfolios themselves hold dividend and sale rights and that no single Managed Portfolio owns more than 5% of the class.
State Street Corporation reported beneficial ownership of 13,604,307 shares of Ardelyx, Inc. common stock, representing 5.5% of the class. The filing shows shared voting power of 12,897,628 shares and shared dispositive power of 13,604,307 shares, with ownership reported on behalf of multiple State Street advisory subsidiaries.
Ardelyx, Inc. reported higher Q1 2026 revenue but remains unprofitable as it invests heavily in commercialization and pipeline growth. Total revenues reached $94.5 million, up from $74.1 million, driven mainly by product sales.
Net product sales were $93.4 million, led by IBSRELA at $70.1 million (up 58%) and XPHOZAH at $23.3 million, roughly flat year over year. The company recorded a net loss of $37.6 million, slightly improved from $41.1 million, as operating expenses grew to support marketing and R&D. Ardelyx ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and $203.5 million of long-term debt, and later refinanced its loan facility to extend maturities and lower interest rates.
Ardelyx reported strong first quarter 2026 growth while remaining loss-making. Total product revenue reached $93.4 million for the quarter ended March 31, 2026, up 38% from $67.8 million a year earlier, driven mainly by IBSRELA sales of $70.1 million, which grew 58% year-over-year.
XPHOZAH contributed $23.3 million in revenue, and total revenue including other items was $94.5 million. Operating expenses rose as Ardelyx invested in commercialization and R&D, leading to a net loss of $37.6 million, or $(0.15) per share, slightly improved from a $41.1 million loss a year earlier. The company ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and reiterated 2026 revenue guidance of $410–$430 million for IBSRELA and $110–$120 million for XPHOZAH, while advancing its pipeline, including the Phase 3 ACCEL trial in chronic idiopathic constipation and preclinical candidate RDX10531.
Ardelyx, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 16, 2026 at 8:30 a.m. Eastern Time. Holders of common stock as of April 22, 2026 can vote online, by phone, mail, or during the live webcast.
Stockholders will vote on electing three Class III directors, an advisory Say‑on‑Pay resolution, how often to hold future Say‑on‑Pay votes, ratification of Ernst & Young LLP as auditor for 2026, and an amendment to the 2014 Equity Incentive Award Plan to add 9,000,000 shares. Ardelyx highlights strong governance practices, including an independent chair, fully independent board committees, a classified board structure, and extensive pay‑for‑performance features and clawback, ownership, and anti‑hedging policies.
Ardelyx, Inc. Schedule 13G/A discloses passive institutional holdings by Millennium-related entities and Integrated Core Strategies. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 18,043,970 shares (7.4%) and Integrated Core Strategies (US) LLC reports 17,721,732 shares (7.2%). The filing is a joint filing documented by a April 24, 2026 Joint Filing Agreement.